- Stern: NBA In Good Shape This Year
- Daytona To Offer Mid-Race Bonus
- Barcelona, Real Madrid Outpacing ManU In R ...
- League Notes
- LPGA Begins Season With Expanded Schedule
- Shortened NBA Season Resulting In Bad Prod ...
- League Notes
- NFL Faces Decisions On L.A., Alumni
- Roger Goodell Delivers State Of NFL Addres ...
- Global RallyCross, SMI Reach Deal
Upcoming Conferences and Events
-
Mar 21-22
-
Mar 22
-
May 23
-
May 30-31
-
Jun 5-7
SBD/Issue 41/Leagues & Governing Bodies
Shot In The Arm: Active MLB Player To Meet With Mitchell
Published November 7, 2007
An active MLB player has "volunteered to speak" in the coming weeks with steroid investigator George Mitchell, "ending the wall of silence Mitchell had encountered in trying to get active players to cooperate without the leverage of subpoena power," according to a source cited by Tom Verducci of SI.com. The source "described the player as one of several players Mitchell wanted to question because of their previous public comments opposing steroid use, not because the player was connected to any steroid use of his own." Yankees DH Jason Giambi so far is the only active player to have met with Mitchell (SI.com, 11/6).
MORE MEETINGS: In L.A., Bill Shaikin reports Angels CF Gary Matthews Jr. today is scheduled to meet with MLB officials in N.Y. about his alleged ordering of HGH. It is "uncertain whether Matthews will be asked simply about the February SI.com report that alleged he was sent a shipment of HGH in 2004 or whether baseball officials have obtained documents that substantiate his involvement with HGH" (L.A. TIMES, 11/7). In S.F., Fainaru-Wada & Williams cite an MLB source who said that Mariners RF Jose Guillen "is expected to be interviewed" by Selig's office about his "purchase of $19,000 worth of performance-enhancing drugs over a three-year period" (S.F. CHRONICLE, 11/7). With Guillen, Matt Williams and Ismael Valdez all named in a S.F. Chronicle report yesterday as recipients of HGH, MLB Senior VP/PR Rich Levin yesterday said that MLB "would look into the most recent disclosure" (N.Y. TIMES, 11/7).







